{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005499","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2026-08-13T20:20:17+00:00","discovered_at":"2026-08-13T20:21:00.358813+00:00","generated_at":"2026-08-13T20:21:09.832655+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech reports Q3 net loss of $5.4M; advances EB06 vitiligo Phase 2","bullets":["Q3 net loss $5.4M ($0.60/share) vs $1.7M ($0.25) year ago; nine-month loss $11.9M ($1.40) vs $5.0M ($0.95).","R&D expenses rose $3.1M to $4.0M in Q3 on EB06 manufacturing and prep; total opex $5.5M vs $1.9M.","Cash and equivalents $10.3M, working capital $6.9M at June 30, 2026.","EB06 Phase 2 vitiligo study prep complete; first sites activating, recruitment to start in coming weeks in Canada.","Paridiprubart exploratory data in ARDS with AKI showed significant mortality reduction and improved MAKE30 endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005499","json":"https://secwatch.observer/filing/0001171843-26-005499.json","markdown":"https://secwatch.observer/filing/0001171843-26-005499.md","text":"https://secwatch.observer/filing/0001171843-26-005499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/0001171843-26-005499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/f8k_081226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:21:09.832655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}